GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (LTS:0H22) » Definitions » EBITDA Margin %

BioInvent International AB (LTS:0H22) EBITDA Margin % : -801.58% (As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is BioInvent International AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. BioInvent International AB's EBITDA for the three months ended in Sep. 2024 was kr-102.31 Mil. BioInvent International AB's Revenue for the three months ended in Sep. 2024 was kr12.76 Mil. Therefore, BioInvent International AB's EBITDA margin for the quarter that ended in Sep. 2024 was -801.58%.


BioInvent International AB EBITDA Margin % Historical Data

The historical data trend for BioInvent International AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB EBITDA Margin % Chart

BioInvent International AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -134.99 -43.42 -1,358.42 -8.32 -437.59

BioInvent International AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -287.66 -430.11 -1,430.63 -3,110.82 -801.58

Competitive Comparison of BioInvent International AB's EBITDA Margin %

For the Biotechnology subindustry, BioInvent International AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's EBITDA Margin % falls into.



BioInvent International AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

BioInvent International AB's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-312.707/71.461
=-437.59 %

BioInvent International AB's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-102.314/12.764
=-801.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioInvent International AB  (LTS:0H22) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


BioInvent International AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines